|
DoP invites application under PLI scheme for bulk drugs to produce two drugs
|
|
GireeshBabu, New Delhi
December 01 , 2025
|
|
|
The Department of Pharmaceuticals (DoP) will provide support under the production linked incentive (PLI) scheme for bulk drugs to eight more firms to produce key ingredients of broad-spectrum carbapenem antibiotic meropenem and antiretroviral drug ritonavir.
The Department, under the PLI scheme for promotion of domestic manufacturing of critical key starting materials (KSMs), drug intermediates (DIs), and active pharmaceutical ingredients (APIs) in the country, called for eligible firms to submit application for manufacturing of these products under the target segment of other chemical synthesis based KSMs, DIs, and APIs.
For meropenem, a maximum of four applicants will be selected in this round, with minimum annual product capacity of 4 MT as per scheme guidelines, for a total product capacity of 16 MT.
For ritonavir, a maximum of four applicants may be selected within minimum annual production capacity of 5MT as per scheme guidelines, for a total production capacity of 20 MT, said the Department.
Eligible applicants may apply through online mode between November 27 and December 26, 2025.
"Various conditions under the scheme, such as allocation according to available capacities, incentive ceiling in respect of products and limit of incentive up to the production tenure, i.e., up to FY2027-28 for chemical synthesis products, would have to be complied with," said the DoP.
Applicants, including their group companies or subsidiaries, who had previously applied under the scheme for the same unsubscribed products and were granted approval, but who subsequently withdrew from the scheme or whose approval was cancelled in line with relevant clause of the scheme guidelines owing to non-performance or other reasons, are not eligible to apply for the same eligible product.
The PLI scheme for bulk drugs has been launched on March 20, 2020, with a financial outlay of Rs. 6,940 crore for the period FY 2020-21 to FY 2029-30, aiming at promotion of domestic manufacturing of 41 identified bulk drugs to address their high import dependence.
In August, this year, the ministry of chemicals and fertilisers, under which the DoP is operating, said that 32 companies have been selected for greenfield production through 48 projects involving 33 APIs/DIs/KSMs.
Till June, 2025, out of the 6-year production tenure of the scheme 3¼ years of implementation stand completed for chemical-synthesis-based products and 2¼ years for fermentation-based products. Against committed investment of Rs. 3,938.5 crore till then, cumulative investment for the projects approved under the scheme exceeded the target, reaching Rs. 4,709 crore.
Domestic production capacity, with minimum domestic value addition of 90% in fermentation-based products and 70% in chemical-synthesis-based products, has been created in respect of 26 APIs/KSMs/DIs till June, 2025, it said. Cumulative sales of Rs. 1,962 crore was reported over the period from FY 2022-23 onwards, including exports of Rs. 479 crore, thereby avoiding imports worth Rs. 1,483 crore, said the Ministry in August.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|